Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03772613 · ClinicalTrials.gov registry record · Phase 2
The Randomized OPTIMAL-ACT Trial
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT03772613: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT03772613 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 180 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03772613, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
The purpose of this study is to find the ideal range of the activated clotting time (ACT) during percutaneous coronary intervention (PCI) that is associated with lowering the rate of undesirable medical outcomes
Interventions
- DRUG Unfractionated heparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2019-02-08 |
| Est. Completion | 2021-10-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03772613
The ClinicalTrials.gov registry entry for NCT03772613 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Unfractionated heparin is the first listed.
NCT03772613 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03772613 about?
NCT03772613 is a clinical study titled "The Randomized OPTIMAL-ACT Trial". The purpose of this study is to find the ideal range of the activated clotting time (ACT) during percutaneous coronary intervention (PCI) that is associated with lowering the rate of undesirable medical outcomes
What is the current status of trial NCT03772613?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2019-02-08. Estimated completion is 2021-10-25.
What interventions are being tested in trial NCT03772613?
The interventions under investigation include: Unfractionated heparin (DRUG).
Who is sponsoring clinical trial NCT03772613?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.